The SIGMA1 gene (Sigma Non-Opioid Intracellular Receptor 1, also known as SIGMAR1) encodes a unique chaperone protein that operates as a ligand-operated molecular chaperone in the endoplasmic reticulum. The Sigma-1 receptor is a distinct pharmacological entity that binds various psychoactive compounds and plays critical roles in cellular homeostasis, calcium signaling, and neuroprotection. This receptor has emerged as an important therapeutic target for neurodegenerative diseases, particularly Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.
| Attribute |
Value |
| Gene Symbol |
SIGMA1 (SIGMAR1) |
| Full Name |
Sigma Non-Opioid Intracellular Receptor 1 |
| Chromosomal Location |
9p13.3 |
| NCBI Gene ID |
10280 |
| Ensembl ID |
ENSG00000147955 |
| UniProt ID |
Q99720 |
| Gene Type |
Protein coding |
| OMIM |
601978 |
The Sigma-1 receptor is a small 223-amino acid integral membrane protein primarily located in the endoplasmic reticulum (ER). It functions as a unique ligand-operated chaperone that can modulate various cellular processes. Unlike classical G-protein coupled receptors, Sigma-1 operates through chaperone-based mechanisms.
- Size: 223 amino acids (~25 kDa)
- Topology: Single transmembrane domain
- Localization: Endoplasmic reticulum, plasma membrane, mitochondria-associated membranes
- Oligomerization: Forms homodimers and higher-order complexes
The Sigma-1 receptor exhibits diverse biological functions:
- Chaperone Activity: Modulates protein folding and trafficking
- Calcium Signaling: Regulates ER calcium homeostasis through IP3R modulation
- Mitochondrial Function: Affects mitochondrial dynamics and bioenergetics
- Neuroprotection: Protects against various cellular stressors
- Lipid Metabolism: Modulates lipid raft composition and signaling
- IP3R Modulation: Controls calcium release from ER
- BDNF Signaling: Enhances neurotrophic factor signaling
- ER Stress Response: Modulates unfolded protein response
- Autophagy Regulation: Controls autophagy flux
Sigma-1 receptor has significant relevance to AD:
- Expression is altered in AD brains
- Agonists protect against amyloid-beta toxicity
- Modulates tau phosphorylation and aggregation
- Enhances BDNF signaling
The receptor shows therapeutic potential in PD:
- Protects dopaminergic neurons
- Modulates mitochondrial function
- May reduce alpha-synuclein aggregation
- Clinical trials with Sigma-1 agonists underway
- Sigma-1 mutations cause juvenile ALS
- Receptor dysfunction leads to motor neuron degeneration
- Agonists show protective effects in models
- Gene therapy approaches being explored
- Huntington's Disease: Neuroprotective effects
- Depression: Antidepressant-like effects of agonists
- Retinopathy: Protective effects in retinal degeneration
- Cancer: Some tumors express Sigma-1
| Variant |
Type |
Effect |
| E102Q |
Missense |
Juvenile ALS |
| L95del |
Deletion |
Motor neuron disease |
| A156T |
Missense |
ALS spectrum |
- Various SNPs associated with disease risk
- Linkage with psychiatric conditions investigated
- Pharmacogenomic considerations for drug response
- Sigma-1 Agonists: Small molecules that activate the receptor
- Antagonists: For conditions where overactivation is problematic
- Allosteric Modulators: Selective targeting
- Donepezil: Sigma-1 agonist in use for AD
- SA-4503: Selective Sigma-1 agonist
- Pentoxyifylline: Sigma-1 modulator
- PRE-084: Selective agonist
- Neurodegenerative disease treatment
- Cognitive enhancement
- Anti-stress effects
- Analgesia
| Partner |
Interaction |
| IP3R |
Calcium regulation |
| BiP |
ER chaperone interaction |
| VDAC |
Mitochondrial coupling |
| BDNF |
Signaling modulation |
¶ Ligand Interactions
- Endogenous Ligands: Neurosteroids (pregnenolone, DHEA)
- Synthetic Agonists: Various pharmaceutical compounds
- Antagonists:rimcazole, haloperidol
- Calcium signaling
- ER stress response
- Autophagy
- Mitochondrial function
Current research focuses on:
- Developing brain-penetrant Sigma-1 agonists
- Understanding receptor structure
- Clinical trials in neurodegenerative diseases
- Biomarker development